

Multimorbidity Pattern and Risk for Mortality Among Patients With Dementia: A Nationwide Cohort Study Using Latent Class Analysis

Che-Sheng Chu^{1,2,3,4*}, Shu-Li Cheng^{5*}, Ya-Mei Bai^{6,7}, Tung-Ping Su^{6,7,8}, Shih-Jen Tsai^{6,7}, Tzeng-Ji Chen^{8,9,10}, Fu-Chi Yang¹¹, Mu-Hong Chen^{6,7}, and Chih-Sung Liang^{12,13}

¹Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

²Center for Geriatrics and Gerontology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

³Non-Invasive Neuromodulation Consortium for Mental Disorders, Society of Psychophysiology, Taipei, Taiwan

⁴Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

⁵Department of Nursing, Mackay Medical College, Taipei, Taiwan

⁶Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan

⁷Department of Psychiatry, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

⁸Department of Psychiatry, Cheng Hsin General Hospital, Taipei, Taiwan

⁹Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

¹⁰Institute of Hospital and Health Care Administration, National Yang Ming Chiao Tung University, Taipei, Taiwan

¹¹Department of Neurology, Tri-Service General Hospital, Taipei, Taiwan

¹²Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, Taipei, Taiwan

¹³Department of Psychiatry, National Defense Medical Center, Taipei, Taiwan

Objective Individuals with dementia are at a substantially elevated risk for mortality; however, few studies have examined multimorbidity patterns and determined the inter-relationship between these comorbidities in predicting mortality risk.

Methods This is a prospective cohort study. Data from 6,556 patients who were diagnosed with dementia between 1997 and 2012 using the Taiwan National Health Insurance Research Database were analyzed. Latent class analysis was performed using 16 common chronic conditions to identify mortality risk among potentially different latent classes. Logistic regression was performed to determine the adjusted association of the determined latent classes with the 5-year mortality rate.

Results With adjustment for age, a three-class model was identified, with 42.7% of participants classified as "low comorbidity class (cluster 1)", 44.2% as "cardiometabolic multimorbidity class (cluster 2)", and 13.1% as "FRINGED class (cluster 3, characterized by FRacture, Infection, NasoGastric feeding, and bleEDing over upper gastrointestinal tract)." The incidence of 5-year mortality was 17.6% in cluster 1, 26.7% in cluster 2, and 59.6% in cluster 3. Compared with cluster 1, the odds ratio for mortality was 9.828 (95% confidence interval [CI]=6.708–14.401; p<0.001) in cluster 2 and 1.582 (95% CI=1.281–1.953; p<0.001) in cluster 3.

Conclusion Among patients with dementia, the risk for 5-year mortality was highest in the subpopulation characterized by fracture, urinary and pulmonary infection, upper gastrointestinal bleeding, and nasogastric intubation, rather than cancer or cardiometabolic comorbidities. These findings may improve decision-making and advance care planning for patients with dementia.

Psychiatry Investig 2023;20(9):861-869

Keywords Dementia; Latent class analysis; Mortality; Multimorbidity.

INTRODUCTION

mentia was the seventh leading cause of death globally, accounting for 1.6 million deaths.¹ Individuals with any type of dementia have an average mortality risk 5.9 times higher than

According to the Global Burden of Disease Study, 2019, de-

Received: April 12, 2023 **Revised:** June 16, 2023 **Accepted:** June 28, 2023

Correspondence: Chih-Sung Liang, MD

Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, No. 60, Xinmin Road, Beitou District, Taipei 11243, Taiwan Tel: +886-2-2895-9808, Fax: +886-222895-7633, E-mail: lcsyfw@gmail.com

Correspondence: Mu-Hong Chen, MD, PhD

Department of Psychiatry, Taipei Veterans General Hospital, No. 201, Sec. 2, Shihpai Road, Beitou District, Taipei 11217, Taiwan Tel: +886-2-28344012, E-mail: kremer7119@gmail.com

rei. 1000 2 20011012, 12 maii. Richler/119@ginan.e

*These authors contributed equally to this work.

© This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

those without dementia.² However, given its phenotypic heterogeneity, with varying symptoms and disease trajectories, survival in such populations is highly variable.^{2,3} Therefore, the development of prediction models for the risk of mortality among individuals with dementia is important for future planning and service provision.

Most previous studies have emphasized a single patient- or disease-specific factor in predicting mortality risk among individuals with dementia, such as age, male sex, presence of comorbidities, bone fracture, stroke, and/or nasogastric (NG) intubation.4-6 However, the single-disease paradigm may not be adequate for individuals with dementia because they frequently have multiple chronic conditions. To date, few studies have examined multiple factors and their inter-relationship(s) in predicting mortality in patients with dementia. Furthermore, most current prediction models for mortality in patients with dementia are limited by several methodological designs that confer a higher risk for bias or diminished generalization and applicability.7 Other concerns include underestimation of physical comorbidities,8 restricted/specific populations, and a shorter mortality prediction period (<1 year).9 For example, a prognostic model using claims data from the Swedish Dementia Registry (SveDem) can predict mortality risk at 3 years among patients with dementia. However, Sve-Dem covers approximately 35% of incident dementia,¹⁰ and patients included in the SveDem are more likely to be male, younger, and healthier, thus limiting the generalizability to other populations.11 In addition, the diagnosis of chronic medical conditions, such as diabetes mellitus, may be underdiagnosed in patients.8 Another study provided the best validated prognostic model for predicting the risk for mortality for only 6 months, and this model applied a specific population of patients with advanced dementia from nursing homes.9

Dementia can complicate chronic conditions and vice versa.12 On average, patients with dementia have 2 to 8 comorbidities.13 Previous large cohort studies involving community-dwelling individuals with dementia found that those with comorbid diabetes and heart disease, such as myocardial infarction, experienced higher mortality during the follow-up period.14,15 Therefore, adopted robust multivariable prediction models must consider not only individual-level risk factors but also their inter-relationships with mortality, particularly in heterogenous diseases such as dementia. Latent class analysis (LCA) can be used to identify distinctive-but unmeasuredsubgroups within a heterogeneous population.¹⁶ Using LCA, it is possible to categorize dementia based on the numbers of patient- and disease-specific factors rather than a single individual risk factor in predicting mortality. The LCA approach has been used in several previous studies investigating the homeless veteran population,¹⁷ acute kidney injury,¹⁸ and type 2 diabetes.¹⁹ To the best of our knowledge, however, no study has used LCA to predict mortality risk in patients with dementia.

To identify which multimorbidity pattern may be associated with an increased risk for mortality, we applied LCA to data from a nationally representative sample of patients with dementia. We hypothesized that there were latent classes of patients with dementia characterized by specific phenotypes and risk for mortality, which may have clinical implications for physicians with regard to early detection and intervention.

METHODS

The nationwide cohort was derived from the Taiwan National Health Research Database (NHIRD), which is audited and released by the Taiwan National Health Research Institute for Scientific Studies.^{20,21} At the end of 2010, the coverage rate for the NHIRD was approximately 99.6% (23 million residents). Comprehensive information regarding insured individuals is housed in the database, including demographic information, clinical visit dates, disease diagnoses, and prescriptions. The insurance claim information of individuals is kept anonymous to maintain privacy. In the present study, using each resident's unique personal identification number, all information was linked. The diagnostic codes used were based on the International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM). The NHIRD has been used extensively in many Taiwanese epidemiological studies.²²⁻²⁴ The study protocol was reviewed by the Institutional Review Board of the Taipei Veterans General Hospital (2018-07-016AC).

Patients ≥65 years of age diagnosed with dementia (ICD-9-CM codes 290.0–290.4, 331.0–331.2, and 294.1), confirmed by board-certified neurologists or psychiatrists at least twice based on comprehensive interviews and clinical judgement between January 1, 2002 and December 31, 2009, were included. The dementia cohort was followed until December 31, 2013 or until death (whichever occurred first). In Taiwan, a diagnosis of dementia needs to be based on the results of blood examinations (complete blood count and biochemistries, iron, thyroid hormone, vitamin B₁₂, folate, and syphilis), psychological tests, and brain imaging. The condition of mortality was identified from the claims data or registry of catastrophic illness.²⁵ The mortality risk in patients with early onset dementia was not examined.

A consensus meeting with a team of neurologists and psychiatrists experienced in dementia care was convened to identify the relevant morbidity conditions. Besides, we consulted several index papers^{14,26-28} addressing morbidities in patients with dementia. Morbid conditions represented the status of conditions or diseases that patients with dementia exhibited upon clinic visits or hospitalization at the time of a diagnosis

Name Name <t< th=""><th>Ū</th><th>roup A</th><th>Group B</th><th>Group C</th><th>Group D</th><th>Group E</th><th>Group F</th><th>5</th><th>Doct hoc (Bonferroni)</th></t<>	Ū	roup A	Group B	Group C	Group D	Group E	Group F	5	Doct hoc (Bonferroni)
Age (y1) 65-69 $70-74$ $75-79$ $80-84$ $85-89$ 20 Fermale 366 (58.0) 607 (53.0) 88 (53.4) 848 (51.3) 565 (56.6) 226 (53.1) 0003 $A-D^{34}$, $A-D^{34}$ Stoke 386 (60.8) 60^{6} (60.8) 1137 (53.1) 212 (12.8) 199 (16.0) 8 (2.3.1) 0003 $A-D^{34}$, $A-D^{34}$ Bore fracture 387 (60.8) 60^{6} (60.8) 1137 (53.9) 13177 212 (12.8) 199 (16.0) $8(2.3)$ 20001 $A-D^{344}$, E_{14} Bore fracture 467 (7.3) 837 (7.3) 237 (54.9) 367 (53.9) 246 (55.9) 246 (57.9) 266 (57.9) 266 (53.9) 266 (53.9) 266 (53.9) 266 (53.9) 266 (53.9) 266 (53.9) 2007 (53.9) 200 (50.1) 276 (5.1) 276 (5.1) 276 (5.1) 296 (53.9) 296 (53.9) 296 (53.9) 296 (53.9) 296 (53.9) 290 (50.0) 290 (50.1) 296 (5.1) 296 (5.1) 296 (5.1) 296 (5.1) 296 (5.1) 296 (5.1) <th>(J)</th> <th>V=635)</th> <th>(N=1,145)</th> <th>(N=1,701)</th> <th>(N=1,654)</th> <th>(N=995)</th> <th>(N=426)</th> <th>کر</th> <th></th>	(J)	V=635)	(N=1,145)	(N=1,701)	(N=1,654)	(N=995)	(N=426)	کر	
Fmmle 366 (58.0) 607 (53.0) 88 (50.4) 84 (51.1) 563 (56.1) 600 A-CP**A Bore fracture 366 (60.8) 67 (5.9) 131 (77) 122 (12.8) 159 (16.0) 98 (33.1) 000 A-CP**A Bore fracture 48 (7.5) 67 (5.9) 131 (77) 122 (12.8) 159 (16.0) 98 (33.1) 000 A-CP**A A-CP**A Bore fracture 48 (7.5) 67 (5.9) 131 (77) 123 (12.8) 159 (16.0) 98 (33.1) 000 A-CP**A A-CP**A Medical history 46 (7.2) 83 (7.2) 134 (9.4) 86 (4.0) 138 (4.3) 70 (7.0) 083 000 A-CP**A D-C Derivation 46 (7.2) 88 (6.4) 138 (8.3) 73 (7.3) 30 (7.0) 083 D-C	e (yr) é	55-69	70-74	75-79	80-84	85-89	≥90		
Stroke 386 (603) 666 (603) 1,137 (66,1) 1,127 (68,1) 664 (667) 273 (64,1) (001) $A CD^{**}_{**} A CE, F_{*}^{*}$ Boxe fracture 48 (7.6) 67 (5.9) 131 (7.7) 212 (12.8) 159 (16.0) 98 (23.0) (001) $A CD^{**}_{**} A CE, F_{*}^{*}$ Medical history 46 (7.2) 83 (7.2) 134 (7.3) 138 (8.3) $73 (7.3)$ 30 (7.0) 0.039 $A CD^{**}_{**} A CB, F_{*}^{*} A CE, F_{*}^{*}$ WrUD 46 (7.2) 83 (7.2) 138 (8.3) $73 (7.3)$ 30 (7.0) 0.001 $A CD, F_{*}^{**} A CB, F_{*}^{*} A B, F_{*}^{*} $	nale 36	8 (58.0)	607 (53.0)	858 (50.4)	848 (51.3)	563 (56.6)	226 (53.1)	0.003	A>C*, C <e*< td=""></e*<>
Bone fracture $48 (7.6)$ $67 (5.9)$ $131 (7.7)$ $212 (12.8)$ $159 (16.0)$ $96 (23.0)$ -0.001 $A CD^{**}, A CE, F_1$ Medical history $46 (7.2)$ $83 (7.2)$ $124 (7.3)$ $138 (8.3)$ $73 (7.3)$ $30 (7.0)$ 0.339 PVD $46 (7.2)$ $83 (7.2)$ $124 (7.3)$ $138 (8.3)$ $73 (7.3)$ $30 (7.0)$ 0.339 PVD $46 (7.2)$ $83 (7.2)$ $124 (7.3)$ $88 (7.3)$ $244 (57.3)$ 0.001 $A -(C, D, E, F)^{**}$ PVD $232 (36.5)$ $48 (7.1)$ $88 (7.3)$ $246 (3.7)$ $144 (3.38)$ 0.001 $A -(C, D, E, F)^{**}$ Dishpicens $314 (9.4)$ $62 (5.1)$ $96 (53.0)$ $96 (53.0)$ $23 (40.0)$ $170 (39.9)$ 0.001 $A -(C, D, E, F)^{**}$ Dishpicens $314 (9.4)$ $62 (5.1)$ $96 (53.0)$ $96 (4.0)$ $170 (4.0)$ $18 (3.7)$ $144 (3.3)$ $96 (4.0)$ $120 (4.2)$ $120 (4.2)$ $120 (4.2)$ $120 (4.2)$ $120 (4.2)$ $120 (4.2)$ $120 (4.2)$ $120 (4$	38 38	6 (60.8)	696 (60.8)	1,133~(66.6)	1,127 (68.1)	664 (66.7)	273 (64.1)	<0.001	A <d*, b<c*,="" b<d**<="" td=""></d*,>
Medical history Medical history 83 (7.2) 83 (7.2) 138 (8.3) 73 (7.3) 30 (7.0) 0.839 PVD 46 (7.2) 83 (4.21) 854 (50.2) 908 (54.9) 536 (53.9) 244 (57.3) 0.001 A-c(C, D, E, P)**, B // Defet COPD 232 (36.5) 482 (42.1) 854 (50.2) 908 (54.9) 536 (53.9) 244 (57.3) 0.001 A-c(C, D, E, P)**, B // Defet Corect 104 (16.4) 188 (16.4) 363 (2.1.3) 386 (23.3) 236 (53.9) 244 (57.3) 0.001 A-c(C, D, E, P)**, B Diabetes 314 (49.4) 629 (54.0) 906 (53.1) 823 (49.0) 170 (39.9) c0001 A-c(C, D, E, P)**, B Dysiphdemia 146 (23.0) 286 (25.0) 90 (53.1) 80 (40.0) 170 (39.9) c0001 A-c(C, D, E, P)**, B Dysiphdemia 146 (23.0) 286 (25.0) 90 (53.1) 857 (86.1) 858 (86.4) c0001 A-c(C, D, E, P)**, A UGI bleeding 23 (50.1) 143 (86.8) 857 (86.1) 86 (86.4) c0001 A-c(B, P)**, A	ne fracture 4	(7.6)	67 (5.9)	131 (7.7)	212 (12.8)	159 (16.0)	98 (23.0)	<0.001	A <d**, a<(e,="" b<(d,="" e,="" f)***,="" f)***,<br="">C<(D, E, F)***, D<f***, e<f*<="" td=""></f***,></d**,>
PVD $46 (72)$ $83 (72)$ $124 (73)$ $138 (8.3)$ $73 (73)$ $30 (70)$ 0.839 COPD $232 (36.5)$ $482 (42.1)$ $854 (50.2)$ $988 (54.9)$ $536 (53.3)$ $244 (57.3)$ 0.001 $\Lambda < (D, P)^{**}, P < (C, D, E, P)^{**}$ Cancer $104 (16.4)$ $188 (16.4)$ $363 (21.3)$ $386 (23.3)$ $224 (37.7)$ 0.001 $\Lambda < (D, P)^{**}, P < (D, P)^{**}, P < (D, P)^{**}$ Dabetes $314 (49.4)$ $629 (54.9)$ $96 (53.1)$ $386 (23.3)$ $244 (37.3)$ 20001 $\Lambda < (D, P)^{**}, P < (D, P)^{**}$	dical history								
COPD 232 (36.5) 482 (4.2.1) 843 (50.2) 908 (54.9) 536 (53.9) 244 (57.3) $(0001$ $A<(C, D, E, P)^{**}$ Cancer 104 (16.4) 188 (16.4) 363 (21.3) 386 (23.3) 220 (22.1) 110 (25.8) $(0001$ $A<(D, P)^{**}$, $B<(C, D, E, P)^{**}$ Dabetes 314 (49.4) 629 (54.9) 904 (53.1) 823 (49.0) 170 (39.9) $(0001$ $A<(C, D, E, P)^{**}$ Dyslipidemia 146 (23.0) 286 (25.0) 596 (53.6) 616 (57.2) 398 (40.0) 170 (39.9) $(001$ $A<(C, D, E, P)^{**}$ Dyslipidemia 146 (23.0) 286 (25.0) 596 (53.6) 616 (57.2) 398 (40.0) 170 (39.9) $(001$ $A<(C, D, E, P)^{**}$ UGIble>ding 23 (5.6) 90 (53.1) 53 (5.1) 146 (35.1) 23 (56.1) 388 (66.4) $(001$ $A < (B, P)^{*}$, $A < (C, D, E, P)^{**}$ Hypertension 500 (78.7) 73 (6.4) 1435 (86.8) 857 (86.1) 388 (66.4) $(001$ $A < (B, P)^{*}$, $A < (C, D, E, P)^{**}$ Iumg infection 21 (3.3) 111 (11.2) 88 (VD 4	6 (7.2)	83 (7.2)	124 (7.3)	138 (8.3)	73 (7.3)	30 (7.0)	0.839	
Cancer 104 (16.4) 188 (16.4) 363 (21.3) 386 (23.3) 220 (22.1) 110 (25.8) <0001 $A < (D, P)^{**}, B > (E, P)^{**}$ Diabetes 314 (49.4) 629 (54.9) 904 (53.1) 823 (49.8) 435 (43.7) 114 (33.8) <0.001 $A > F^{***}, B > (E, P)^{**}, D > F^{***}$ Dyslipidemia 146 (23.0) 286 (25.0) 596 (35.0) 616 (37.2) 398 (40.0) 170 (39.9) <0.001 $A < (D, F)^{**}, A > (E, F)^{**}, A UGIbleeding 23 (3.6) 34 (3.0) 90 (5.3) 66 (4.0) 51 (5.1) 25 (5.9) 0015 A < (D, F)^{*}, A $	COPD 23	(2 (36.5)	482 (42.1)	854 (50.2)	908 (54.9)	536 (53.9)	244 (57.3)	<0.001	$A<(C, D, E, F)^{***}, B<(C, D, E, F)^{***}$
Diabetes $314(49.4)$ $629(54.9)$ $904(53.1)$ $823(49.8)$ $435(43.7)$ $144(33.8)$ 6001 $\Lambda > F^{\text{p+ss}}$, $B > C(L)E, F)^{\text{ss}}$ Dyslipidemia $146(23.0)$ $286(25.0)$ $596(35.0)$ $616(372)$ $398(40.0)$ $170(39.9)$ $c0001$ $\Lambda < (C, D, E, P)^{\text{ss}}$ UGI bleeding $23(3.6)$ $34(3.0)$ $90(5.3)$ $66(4.0)$ $51(5.1)$ $25(5.9)$ 0.015 $\Lambda < (C, D, E, P)^{\text{ss}}$ UGI bleeding $20(78.7)$ $974(85.1)$ $146(8.7)$ $170(10.3)$ $111(11.2)$ $68(16.0)$ 0.001 $\Lambda < (B, +A < C, L)$ Imginfection $21(3.3)$ $73(6.4)$ $148(8.7)$ $170(10.3)$ $111(11.2)$ $68(16.0)$ 0.001 $\Lambda < B^{\text{s}} + \Lambda < C, L)$ Imginfection $21(3.3)$ $73(6.4)$ $148(8.7)$ $170(10.3)$ $111(11.2)$ $68(16.0)$ 0.001 $\Lambda < B^{\text{s}} + \Lambda < C, L)$ Imginfection $21(3.3)$ $73(4.1)$ $132(11.6)$ $220(13.3)$ $140(14.1)$ $89(20.9)$ 0.001 $\Lambda < B^{\text{s}} + \Lambda < C^{\text{s}} + \Lambda < C^{\text{s}} + \Lambda < L^{\text{s}} + \Lambda < L^{\text$	Cancer 10	14 (16.4)	188(16.4)	363 (21.3)	386 (23.3)	220 (22.1)	110 (25.8)	<0.001	A<(D, F)**, B<(C, E)*, B <d***, b<f**<="" td=""></d***,>
Dyslipidemia146 (23.0)286 (25.0)596 (35.0)616 (37.2)398 (40.0)170 (39.9) (0.01) $A<(C, D, F)^{**}$ UGI bleding23 (3.6)34 (3.0)90 (5.3)66 (4.0)51 (5.1)25 (5.9)0.015 B Hypertension500 (78.7)974 (85.1)1,468 (86.4)1,435 (86.8)857 (86.1)368 (86.4) $A<(B, F)^*, A$	Jiabetes 31	4 (49.4)	629 (54.9)	904 (53.1)	823 (49.8)	435 (43.7)	144 (33.8)	<0.001	A>F***, B>(E, F)***, C>(E, F)***, D>E*, D>F***, E>F**
UGI bleeding23 (3.6)34 (3.0)90 (5.3) $66 (4.0)$ $51 (5.1)$ $25 (5.9)$ 0.015 \mathbf{M} Hypertension $500 (78.7)$ $974 (85.1)$ $1,435 (86.4)$ $1,435 (86.3)$ $857 (86.1)$ $368 (86.4)$ 0.001 $\mathbf{A} < (\mathbf{B}, \mathbf{F})^*, \mathbf{A} < (\mathbf{C}, \mathbf{D}_1)$ Lung infection $21 (3.3)$ $73 (6.4)$ $1,435 (86.3)$ $170 (10.3)$ $111 (11.2)$ $68 (16.0)$ <0.001 $\mathbf{A} < (\mathbf{B}, \mathbf{A}, \mathbf{A} < (\mathbf{C}, \mathbf{D}_1)$ Nasogastric tube $47 (7.4)$ $135 (11.8)$ $202 (11.9)$ $220 (13.3)$ $140 (14.1)$ $89 (20.9)$ <0.001 $\mathbf{A} < (\mathbf{B}^*, \mathbf{A} < (\mathbf{C}^{**}, \mathbf{A} < (\mathbf{C}^{**}, \mathbf{A})$ Nasogastric tube $102 (16.1)$ $184 (16.1)$ $332 (19.5)$ $326 (19.7)$ $180 (18.1)$ $89 (20.9)$ <0.001 $\mathbf{A} < (\mathbf{B}^*, \mathbf{A} < (\mathbf{C}^{**}, \mathbf{A} < (\mathbf{C}^{**}, \mathbf{A})$ Urinary infection $102 (16.1)$ $184 (16.1)$ $332 (19.5)$ $326 (19.7)$ $180 (18.1)$ $89 (20.9)$ 0.007 $\mathbf{A} < (\mathbf{B}^*, \mathbf{A} < (\mathbf{C}^{**}, \mathbf{A} < (\mathbf$	Jyslipidemia 14	6 (23.0)	286 (25.0)	596 (35.0)	616 (37.2)	398 (40.0)	170 (39.9)	<0.001	$A<(C, D, E, F)^{***}, B<(C, D, E, F)^{***}$
Hypertension500 (78.7) 974 (85.1) $1,469$ (86.4) $1,435$ (86.8) 857 (86.1) 368 (86.4) <0.001 $A<(B, F)^*, A<(C, D_1)$ Lung infection 21 (3.3) 73 (6.4) 148 (8.7) 170 (10.3) 111 (11.2) 68 (16.0) <0.001 $A<(B^*, A<(C, D_1)$ Nasogastric tube 47 (7.4) 135 (11.8) 202 (11.9) 220 (13.3) 140 (14.1) 89 (20.9) <0.001 $A<(B^*, A<(C, P_1)$ Urinary infection 102 (16.1) 184 (16.1) 332 (19.5) 326 (19.7) 180 (18.1) 99 (23.2) 0.007 $A<(B^*, A<(C, *, A<(-F))$ Wyocardial infarction 18 (2.8) 38 (3.3) 84 (4.9) 81 (4.9) 45 (4.5) 16 (3.8) 0.073 $CMyocardial infarction18 (2.8)38 (3.3)84 (4.9)81 (4.9)35 (8.2)0.007A<(B^*, A<(C, F))^*Chronic kidney disease61 (9.6)131 (11.4)196 (11.5)107 (10.8)35 (8.2)0.0730.073Coronary artery disease316 (49.8)599 (52.3)997 (58.5)990 (59.9)584 (58.7)236 (55.4)0.001A<(C, B)^{**}, ACompactive heart failure100 (15.7)214 (18.7)416 (24.5)166 (27.0)137 (32.2)0.001A<(C, B)^{**}, B<$	JGI bleeding 2	3 (3.6)	34 (3.0)	90 (5.3)	66 (4.0)	51 (5.1)	25 (5.9)	0.015	B <c*< td=""></c*<>
Lung infection21 (3.3)73 (6.4)148 (8.7)170 (10.3)111 (11.2)68 (16.0) <0.001 $A < B^*, A < (C, D_1)$ Nasogastric tube $47 (7.4)$ 135 (11.8)202 (11.9)220 (13.3)140 (14.1)89 (20.9) <0.001 $A < B^*, A < (C, D_1)$ Nasogastric tube $47 (7.4)$ 135 (11.8)202 (11.9)220 (13.3)140 (14.1)89 (20.9) <0.001 $A < B^*, A < (C, D_1)$ Urinary infection102 (16.1)184 (16.1)332 (19.5)326 (19.7)180 (18.1)99 (23.2)0.007 $C < F^{***}$, AMyocardial infarction18 (2.8)38 (3.3)84 (4.9)81 (4.9)45 (4.5)16 (3.8)0.073Myocardial infarction18 (2.8)38 (3.3)84 (4.9)81 (4.9)45 (4.5)16 (3.8)0.073Chronic kidney disease61 (9.6)131 (11.4)196 (11.5)190 (11.5)107 (10.8)35 (8.2)0.295Coronary artery disease316 (49.8)599 (52.3)995 (58.5)990 (59.9)584 (58.7)236 (55.4) <0.001 $A < (C, E)^{**}, A < D^*$ Congestive heart failure100 (15.7)214 (18.7)461 (27.9)269 (27.0)137 (32.2) <0.001 $A < (C, D, E, F)^{***}, B < 0.001$ 5-vear mortality94 (14.8)213 (18.6)448 (26.3)528 (31.9)315 (31.7)179 (42.0) <0.001 $A < (C, D, E, F)^{***}, B < 0.001$	Hypertension 50	0 (78.7)	974 (85.1)	1,469~(86.4)	1,435~(86.8)	857 (86.1)	368 (86.4)	<0.001	A<(B, F)*, A<(C, D)***, A <e**< td=""></e**<>
Nasogastric tube $47 (7.4)$ $135 (11.8)$ $202 (11.9)$ $220 (13.3)$ $140 (14.1)$ $89 (20.9)$ <0.001 $A < B^*, A < C^{**}, A < C^$	Jung infection 2	1 (3.3)	73 (6.4)	148 (8.7)	170 (10.3)	111 (11.2)	68 (16.0)	<0.001	A <b*, a<(c,="" b<(d,="" d,="" e)**,<br="" e,="" f)***,="">B<f***, c<f**,="" d<f*<="" td=""></f***,></b*,>
Urinary infection 102 (16.1) 184 (16.1) 332 (19.5) 326 (19.7) 180 (18.1) 99 (23.2) 0.007 F Myocardial infaction 18 (2.8) 38 (3.3) 84 (4.9) 81 (4.9) 45 (4.5) 16 (3.8) 0.073 F Chronic kidney disease 61 (9.6) 131 (11.4) 196 (11.5) 190 (11.5) 107 (10.8) 35 (8.2) 0.295 Coronary artery disease 316 (49.8) 599 (52.3) 995 (58.5) 990 (59.9) 584 (58.7) 236 (55.4) <0.001	Vasogastric tube 4	17 (7.4)	135 (11.8)	202 (11.9)	220 (13.3)	140 (14.1)	89 (20.9)	<0.001	A <b*, a<(d,="" a<c**,="" b<f***,<br="" e,="" f)***,="">C<f***, d<f**,="" e<f*<="" td=""></f***,></b*,>
Myocardial infarction18 (2.8)38 (3.3)84 (4.9)81 (4.9)45 (4.5)16 (3.8)0.073Chronic kidney disease61 (9.6)131 (11.4)196 (11.5)190 (11.5)107 (10.8)35 (8.2)0.295Coronary artery disease316 (49.8)599 (52.3)995 (58.5)990 (59.9)584 (58.7)236 (55.4)<0.001	Jrinary infection 10	12 (16.1)	184 (16.1)	332 (19.5)	326 (19.7)	180(18.1)	99 (23.2)	0.007	B <f*< td=""></f*<>
Chronic kidney disease $61 (9.6)$ $131 (11.4)$ $196 (11.5)$ $100 (11.5)$ $107 (10.8)$ $35 (8.2)$ 0.295 Coronary artery disease $316 (49.8)$ $599 (52.3)$ $995 (58.5)$ $990 (59.9)$ $584 (58.7)$ $236 (55.4)$ <0.001 $A<(C, E)^{**}, ACongestive heart failure100 (15.7)214 (18.7)416 (24.5)461 (27.9)269 (27.0)137 (32.2)<0.001A<(C, D, E, F)^{***}, B<$	Vyocardial infarction	8 (2.8)	38 (3.3)	84 (4.9)	81 (4.9)	45 (4.5)	16 (3.8)	0.073	
Coronary artery disease 316 (49.8) 599 (52.3) 995 (58.5) 990 (59.9) 584 (58.7) 236 (55.4) <0.001 A<(C, E)**, A <d*< th=""> Congestive heart failure 100 (15.7) 214 (18.7) 416 (24.5) 461 (27.9) 269 (27.0) 137 (32.2) <0.001</d*<>	Chronic kidney disease 6	(1) (9.6)	131 (11.4)	196 (11.5)	190(11.5)	107~(10.8)	35 (8.2)	0.295	
Congestive heart failure 100 (15.7) 214 (18.7) 416 (24.5) 461 (27.9) 269 (27.0) 137 (32.2) <0.001 A<(C, D, E, F)***, B< 5-vear mortality 94 (14.8) 213 (18.6) 448 (26.3) 528 (31.9) 315 (31.7) 179 (42.0) <0.001	Coronary artery disease 31	6 (49.8)	599 (52.3)	995 (58.5)	990 (59.9)	584 (58.7)	236 (55.4)	<0.001	A<(C, E)**, A <d***, b<(c,="" b<d**<="" e)*,="" td=""></d***,>
5-year mortality 94 (14.8) 213 (18.6) 448 (26.3) 528 (31.9) 315 (31.7) 179 (42.0) <0.001 A<(C, D, E, F)**	Congestive heart failure 10	0 (15.7)	214 (18.7)	416 (24.5)	461 (27.9)	269 (27.0)	137 (32.2)	<0.001	A<(C, D, E, F)***, B <c**, b<(d,="" c<f*<="" e,="" f)***,="" td=""></c**,>
	ear mortality 9	14 (14.8)	213 (18.6)	448 (26.3)	528 (31.9)	315 (31.7)	179 (42.0)	<0.001	A<(C, D, E, F)***, B<(C, D, E, F)***, C <d**, c<f***,="" d<f**,="" e<f**<="" td=""></d**,>

www.psychiatryinvestigation.org 863

of dementia. Acute clinical conditions (existing within 3 months before the first diagnosis of dementia) were also included. Finally, the following 16 morbidity conditions were included: diabetes mellitus; hypertension; dyslipidemia; coronary artery disease; congestive heart failure; myocardial infarction; cancer; stroke; bone fracture; peripheral vascular disease; chronic kidney disease; chronic obstructive pulmonary disease (COPD); upper gastrointestinal (UGI) bleeding; pulmonary infection; urinary infection; and NG intubation.

Statistical analysis

Patients with dementia were divided into six groups based on age (65–69, 70–74, 75–79, 80–84, 85–89, and ≥90 years). The 16 morbidity conditions (absence vs. presence) and sex were dichotomized. Descriptive statistics were used to describe the demographic characteristics and prevalence of each morbidity condition. The distribution of demographics and the prevalence of morbidity conditions among the different age groups were examined using analysis of variance with post hoc Bonferroni correction.

LCA was used to generate clusters of morbidity conditions among participants, which could identify a set of underlying subgroups of individuals based on the intersection of multiple observed characteristics. In practice, it is unlikely that every observed characteristic actually reflects a unique and important type of individual; therefore, it may be helpful to establish a smaller set of subgroups with specific multimorbidity patterns that may correlate with mortality. Such subgroups are unobserved and are referred to as "latent classes." The observed categorical variables that comprised the latent classes in this analysis included sex and the 16 morbidity conditions. Age was also included as a covariate because it is strongly associated with mortality. The LCA model was fit over two, three, and four. The class with the smallest Bayesian information criterion (BIC) and Akaike information criterion (AIC) was considered to be a good fit. Participants were classified into latent classes based on the maximum predicted probability. The predicted latent classes and the risk for mortality were examined using logistic regression, with adjustment for sex, age, and the 16 morbidity conditions. In summary, LCA analysis often followed three steps: 1) to build a latent class model for a set of observed discrete variables; 2) subjects are assigned to latent classes based on their highest membership probability; and 3) using these predicted scores to assess the association between the assigned class membership and external variables via simple cross-tabulations or multinomial logistic regression analysis.

We chose 5-year mortality rate based on our previous study, which shown the mean survival time from diagnosis was 5.8 and 4.6 years for Alzheimer's disease (AD) and non-AD dementia, respectively.² Data management and analysis were

864 Psychiatry Investig 2023;20(9):861-869

performed using Stata version 16 (StataCorp LLC, College Station, TX, USA) and the R-Project version 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria). Differences with a two-tailed p<0.05 were considered to be statistically significant.

RESULTS

Descriptive summaries of dementia according to age group

Demographic characteristics of patients with dementia for each age group are summarized in Table 1. Patients were divided into six groups according to age (in years): A, 65–69; B, 70–74; C, 75–79; D, 80–84; E, 85–89; and F, ≥90. The sample sizes in each group ranged from 426 in group F (≥90 years) to 1,701 in group C (75–79 years). Females constituted most patients across the groups, with group A (65–69 years) containing the highest proportion of female patients. The 5-year mortality rate ranged from 14.8% to 42.0%, with group F (≥90 years) exhibiting the highest mortality rate. There were significant differences in age, sex, stroke, bone fracture, medical history, and 5-year mortality across the groups. Post hoc analysis using the Bonferroni method was performed to compare baseline differences between groups.

LCAs

Based on the AIC and BIC, the three-class model was the



Figure 1. Distribution of dementia group by latent class analysis. Group_A: Patient's age of 65–69 years. Group_B: Patient's age of 70–74 years. Group_C: Patient's age of 75–79 years. Group_D: Patient's age of 80–84 years. Group_E: Patient's age of 85–89 years. Group_F: Patient's age of ≥90 years. Cluster_1: Low comorbidity class. Cluster_2: Cardiometabolic multimorbidity class. Cluster_3: FRINGED class (characterized by FRacture, Infection, NasoGastric feeding, and bleEDing over upper gastrointestinal tract).

most parsimonious with optimal clinical interpretability and class size. Because age represents the most significant risk factor for higher mortality in patients with dementia,^{2,29} the LCA model was adjusted for age. Individuals from each age group were equally distributed in clusters 1, 2, and 3 (Figure 1).

Because comorbid disease has been reported to be the main predictor of mortality in community-dwelling older adults with dementia,¹⁵ three clusters were defined: cluster 1, low comorbidity class (n=2,800); cluster 2, cardiometabolic multimorbidity class, defined as \geq 2 cardiometabolic conditions³⁰ (n= 2,900); and cluster 3, FRINGED class, which was characterized by FRacture, Infection, NasoGastric feeding, and bleEDing over the UGI tract (n=856).

The baseline characteristics of each latent class are summa-

Fable 2. Descript	tive summaries	of dementia	group by	y latent	class ana	alysis

rized in Table 2. There was no significant difference in age across the three clusters. Most patients were female in clusters 1 and 2, while most were male in cluster 3. Regarding stroke and bone fracture, the proportion was highest in cluster 3 (82.1% and 21.1%, respectively). The prevalence of several medical histories, including COPD, UGI bleeding, lung infection, NG intubation, and urinary infection, was lowest in patients in cluster 1. The clusters were numbered according to increased 5-year mortality risk: cluster 1 had the lowest (17.6%), whereas cluster 3 had the highest (59.6%). Important characteristics of the patients comprising cluster 3 are shown in Figure 2. Several different types of comorbidities were observed in cluster 3, in which stroke (82.1%), NG intubation (78.7%), and COPD

(70.9%) were most common.

	Cluster 1	Cluster 2	Cluster 3	р	Post hoc (Bonferroni)
Total	2,800 (42.7)	2,900 (44.2)	856 (13.1)		
Group A	390 (13.9)	213 (7.3)	32 (3.7)	< 0.001	
Group B	582 (20.8)	473 (16.3)	90 (10.5)		
Group C	694 (24.8)	805 (27.8)	202 (23.6)		
Group D	616 (22.0)	782 (27.0)	256 (29.9)		
Group E	377 (13.5)	458 (15.8)	160 (18.7)		
Group F	141 (5.0)	169 (5.8)	116 (13.6)		
Age (yr)	77.8±7.1	79.3±6.5	81.6±6.8		
Female	1,447 (51.7)	1,640 (56.6)	383 (44.7)	< 0.001	1<2*, 1>3*, 2>3*
Stroke	1,319 (47.1)	2,257 (77.8)	703 (82.1)	< 0.001	1<(2, 3)***, 2<3*
Bone fracture	234 (8.4)	300 (10.3)	181 (21.1)	< 0.001	1<2**, 1<3*, 2<3***
Medical history					
PVD	97 (3.5)	329 (11.3)	68 (7.9)	< 0.001	1<(2, 3)***, 2>3**
COPD	849 (30.3)	1,800 (62.1)	607 (70.9)	< 0.001	1<(2, 3)***, 2<3***
Cancer	427 (15.3)	710 (24.5)	234 (27.3)	< 0.001	1<(2, 3)***
Diabetes	917 (32.8)	1,855 (64.0)	477 (55.7)	< 0.001	1<(2, 3)***, 2>3**
Dyslipidemia	255 (9.1)	1,573 (54.2)	384 (44.9)	< 0.001	1<(2, 3)***, 2>3***
UGI beeding	47 (1.7)	113 (3.9)	129 (15.1)	< 0.001	1<(2, 3)***, 2<3***
Hypertension	1,967 (70.3)	2,827 (97.5)	809 (94.5)	< 0.001	1<(2, 3)***, 2>3**
Lung infection	60 (2.1)	48 (1.7)	483 (56.4)	< 0.001	1<3***, 2<3***
Nasogastric tube	92 (3.3)	67 (2.3)	674 (78.7)	< 0.001	1<3***, 2<3***
Urinary infection	288 (10.3)	450 (15.5)	485 (56.7)	< 0.001	1<(2, 3)***, 2<3***
Myocardial infarction	0 (0.0)	232 (8.0)	50 (5.8)	< 0.001	1<(2, 3)***
Chronic kidney disease	160 (5.7)	418 (14.4)	142 (16.6)	< 0.001	1<2***, 1<3***
Coronary artery disease	553 (19.8)	2,625 (90.5)	542 (63.3)	< 0.001	1<(2, 3)***, 2>3***
Congestive heart failure	91 (3.3)	1,192 (41.1)	314 (36.7)	< 0.001	1<(2, 3)***
5-year mortality	494 (17.6)	773 (26.7)	510 (59.6)	< 0.001	1<(2, 3)**, 2>3***

Values are presented as mean±standard deviation or number (%). Group A: Patient's age of 65–69 years. Group B: Patient's age of 70–74 years. Group C: Patient's age of 75–79 years. Group D: Patient's age of 80–84 years. Group E: Patient's age of 85–89 years. Group F: Patient's age of ≥ 90 years. Cluster 1: Low comorbidity class. Cluster 2: Cardiometabolic multimorbidity class. Cluster 3: FRINGED class (characterized by FRacture, Infection, NasoGastric feeding, and bleEDing over upper gastrointestinal tract). p-value indicates the result of omnibus test. *p<0.05; **p<0.01; ***p<0.001. PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease; UGI bleeding, upper gastrointestinal bleeding



Figure 2. Important characteristics in cluster 3. Cluster 3: FRINGED class (characterized by FRacture, Infection, NasoGastric feeding, and bleEDing over upper gastrointestinal tract). NG, nasogastric; COPD, chronic obstructive pulmonary disease; UGI bleeding, upper gastrointestinal bleeding.

Predictability of 5-year mortality of latent class and other variables

The comorbidity and characteristic clusters among patients with dementia from the LCA are shown in Supplementary Figure 1 (in the online-only Data Supplement). Associations of 5-year mortality with the latent classes are summarized in Table 2. Cluster 1 was set as the reference group for analysis. Patients in clusters 3 (odds ratio [OR]=9.828 [95% confidence interval, CI=6.708-14.401]; p<0.001) and clusters 2 (OR=1.582 [95% CI=1.281-1.953]; p<0.001) had the highest and secondhighest 5-year mortality rate, respectively, compared with those in cluster 1 during the follow-up period (Table 3). Regarding different age groups, age-dependent risk for mortality was found in groups C to F (group C, OR=1.660 [95% CI= 1.285-2.146]; group D, OR=2.067 [95% CI=1.601-2.668]; group E, OR=2.139 [95% CI=1.630-2.806]; and group F, OR= 2.829 [95% CI=2.066-3.874]). Patients in group C to group F exhibited a higher 5-year mortality rate compared with those in group A and there was no difference regarding 5-year mortality rate between Group A and B. Significant risk factors for higher 5-year mortality identified in this study included male sex (OR=1.705 [95% CI=1.510-1.927]), cancer (OR=1.709 [95% CI=1.491-1.959]), diabetes (OR=1.194 [95% CI=1.053-1.352]), chronic kidney disease (OR=1.632 [95% CI=1.370-1.943]), and congestive heart failure (OR=1.214 [95% CI=1.050-1.403]) (all p<0.05). Other factors associated with a lower 5-year mortality included lung infection (OR=0.649 [95% CI=0.501-0.841]), NG intubation (OR=0.613 [95% CI=0.457-0.822]), and coronary artery disease (OR=0.827 [95% CI=0.705-0.972]). Because the latent groups have included significant variance of the 5-year mortality, the other variables were considered confounding factors. When we removed the latent groups from

Table 3. Predictability of 5-year mortality of latent class and of	other
variables	

Variables	OR	95% CI	р
Latent class			
Class 3 vs. Class 1	9.828	6.708-14.401	< 0.001
Class 2 vs. Class 1	1.582	1.281-1.953	< 0.001
Original age group			
Group F vs. Group A	2.829	2.066-3.874	< 0.001
Group E vs. Group A	2.139	1.630-2.806	< 0.001
Group D vs. Group A	2.067	1.601-2.668	< 0.001
Group C vs. Group A	1.660	1.285-2.146	< 0.001
Group B vs. Group A	1.201	0.911-1.584	0.194
Male vs. Female	1.705	1.510-1.927	< 0.001
Stroke	0.883	0.772-1.009	0.067
Bone fracture	1.148	0.954-1.381	0.143
Medical history			
PVD	1.007	0.811-1.252	0.947
COPD	1.038	0.915-1.177	0.567
Cancer	1.709	1.491-1.959	< 0.001
Diabetes	1.194	1.053-1.352	0.006
Dyslipidemia	0.905	0.790-1.037	0.151
UGI bleeding	1.078	0.820-1.418	0.589
Hypertension	0.978	0.807-1.184	0.816
Lung infection	0.649	0.501-0.841	0.001
Nasogastric tube	0.613	0.457-0.822	0.001
Urinary infection	1.117	0.953-1.309	0.171
Myocardial infarction	1.179	0.897-1.549	0.238
Chronic kidney disease	1.632	1.370-1.943	< 0.001
Coronary artery disease	0.827	0.705-0.972	0.021
Congestive heart failure	1.214	1.050-1.403	0.009

Group A: Patient's age of 65–69 years. Group B: Patient's age of 70– 74 years. Group C: Patient's age of 75–79 years. Group D: Patient's age of 80–84 years. Group E: Patient's age of 85-89 years. Group F: Patient's age of \geq 90 years. OR, odd ratio; CI, confidence interval; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease; UGI bleeding, upper gastrointestinal bleeding

the logistic model, the coefficients of lung infection and NG intubation were changed to >1: lung infection (1.334; 1.097– 1.622) and NG intubation (1.561; 1.314–1.854). The coefficient was no longer significant (0.904; 0.866–1.098) for coronary artery disease. The important characteristics exhibited by patients in cluster 3 are summarized in Figure 2.

DISCUSSION

This is the first study to show that the combination of multimorbidity and patient characteristics using LCA can predict 5-year mortality risk among a heterogeneous sample of patients with dementia. We found that a three-class solution yielded the best-fitting classification model. More specifically, we observed that the FRINGED class (i.e., cluster 3) and cardiometabolic multimorbidity class (i.e., cluster 2) were predictive of mortality within the 5-year follow-up compared to the low comorbidity burden class (i.e., cluster 1).

Based on our LCA, 13.1% of patients with dementia were classified as cluster 3, and this population had the highest 5-year mortality risk (59.6%) compared to those with a low comorbidity burden (17.6%). Stroke accounted for the largest percentage of comorbid disease in cluster 3 (82.1%), followed by NG intubation (78.7%), and COPD (70.9%). Furthermore, lung and urinary infections were also both highly prevalent in cluster 3. The clinical complexity of comorbidity among this subset of individuals with dementia poses challenges for primary and secondary care. For example, stroke is an established, strong, and modifiable risk factor for all-cause dementia,³¹ whereas post-stroke dementia exhibited a steep decline in global cognition compared to stroke survivors without dementia.32 In addition, 41.3% of individuals with dementia were hospitalized due to pneumonia and urinary tract infection (UTI)-both of which are avoidable and treatablebut, nevertheless, commonly lead to markedly higher mortality.33 The presence of coexisting comorbidities may contribute to a more negative impact on dementia management. Thus, understanding the influence of comorbidities on the pathogenesis of dementia may help prevent disease progression.³⁴

Patients with dementia classified into cluster 3 were similar to those with frailty, a geriatric syndrome characterized by age-related, decreased physiological reserve and increased vulnerability to stressors.³⁵ Studies have found that frailty is associated with an increased risk for adverse outcomes, including stroke,³⁶ fracture,³⁷ and infection.³⁸ A prospective co-hort study of 1,152 community-dwelling older adults with an 18-year follow-up reported that those with frailty had a 3.78 times higher risk for mortality.³⁹ In addition, the prevalence of frailty among older adults living with dementia in a community-dwelling setting ranged from 24.3% to 98.9%.⁴⁰ Although frailty is not a disease per se, it profoundly influences disease expression. Dementia alone may contribute to excessive mortality, which may be further increased by comorbid frailty.

With the progression of dementia, the rate of comorbidities and severity increased. Notably, these physical comorbidities were treatable and preventable. One study reported that pneumonia, chronic heart failure, and UTI accounted for two-thirds of all potentially preventable admissions, followed by dehydration and duodenal ulcer among patients with dementia.⁴¹ Similarly, patients with dementia are less likely to undergo treatment for hypertension⁴² or age-related macular degeneration.⁴³ Furthermore, chronic physical conditions are frequently neglected, with 42% of unplanned admissions >70 years of age having dementia.³³ These under-diagnosed and under-treated comorbidities among patients with dementia lead to higher usage of health services, hospital admission(s), prescriptions, and mortality, particularly for patients with AD.^{5,44} Understanding the inter-relationship between comorbidities and dementia is important for the development of effective, patient-tailored treatment and public health policies.

It would be difficult to compare the present findings with previous research due to differences in basic demographic characteristics and health care systems in heterogeneous populations, such as those with dementia.^{7,8,45} Several factors, such as the rate of underdiagnosis of dementia, ascertainment of dates of death, medical diagnoses, and medications may introduce a high risk of bias or concerns regarding applicability.7,45,46 Therefore, uncertainty in predicting survival probabilities remains one of the barriers to enhancing advance care planning and shared decision-making in dementia,47 particularly in an era of rising prevalence of dementia. The application of LCA in the present study yielded more information about several characteristics that may interact with one another in impacting survival. By doing this, we extended previous work that predominantly emphasized the influence of individual risk factors, such as living alone,48 increased frailty,49 and multimorbidity,50 on mortality to identify latent classes of dementia.

Several limitations of our study should be considered when interpreting our findings. First, LCA can vary over time and across cohorts; as such, additional replication and validation are required. Second, survival after diagnosis of dementia may vary according to ethnicity.⁵¹ This study was specific to the dementia population derived from the national claims dataset in Taiwan. Thus, our findings may not be generalizable to other ethnicities. Third, the study did not distinguish among the different types of dementia.² Fourth, several variables, including laboratory values and lifestyle (e.g., physical activity and tobacco smoking), were not available in the dataset and may have influenced the findings.

In conclusion, the present study identified three qualitatively separate, broad multimorbidity clusters using LCA in a nationally representative Taiwanese sample of patients with dementia. We found that the different latent clusters could predict the 5-year mortality rate based on numbers of patientand disease-specific factors. These results may inform shared decision-making practices and advance care planning in patients with dementia.

Supplementary Materials

The online-only Data Supplement is available with this ar-

ticle at https://doi.org/10.30773/pi.2023.0112.

Availability of Data and Material

The data are available on request from the corresponding author without any access criteria.

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Che-Sheng Chu. Data curation: Mu-Hong Chen, Chih-Sung Liang. Formal analysis: Mu-Hong Chen. Funding acquisition: Che-Sheng Chu, Shu-Li Cheng. Investigation: Che-Sheng Chu, Chih-Sung Liang. Methodology: Mu-Hong Chen, Chih-Sung Liang. Project administration: Shih-Jen Tsai. Resources: Shih-Jen Tsai, Tzeng-Ji Chen. Software: Mu-Hong Chen, Chih-Sung Liang. Supervision: Mu-Hong Chen, Chih-Sung Liang. Validation: Ya-Mei Bai, Chih-Sung Liang. Visualization: Ya-Mei Bai, Fu-Chi Yang. Writing—original draft: Che-Sheng Chu. Writing—review & editing: all authors.

ORCID iDs

Che-Sheng Chu	https://orcid.org/0000-0002-6911-1839
Shu-Li Cheng	https://orcid.org/0000-0002-1523-8519
Ya-Mei Bai	https://orcid.org/0000-0003-3779-9074
Tung-Ping Su	https://orcid.org/0000-0002-9049-8935
Shih-Jen Tsai	https://orcid.org/0000-0002-9987-022X
Tzeng-Ji Chen	https://orcid.org/0000-0002-8350-0232
Fu-Chi Yang	https://orcid.org/0000-0001-6831-3634
Mu-Hong Chen	https://orcid.org/0000-0001-6516-1073
Chih-Sung Liang	https://orcid.org/0000-0003-1138-5586

Funding Statement

The study was supported by grant from Taipei Veterans General Hospital (V106B-020, V107B-010, V107C-181, V108B-012), Kaohsiung Veterans General Hospital (KGVGH-110-051, VGHKS-109-070, KSVGH111-082, KSVGH111-181), Yen Tjing Ling Medical Foundation (CI-110-30) and Ministry of Science and Technology, Taiwan (107-2314-B-075-063-MY3, 108-2314-B-075-037, MOST-109-2314-B-075B-001-MY2) and MacKay Medical College, Taiwan (MMC-RD-111-1B-P003, for SLC). The funding source had no role in any process of our study.

REFERENCES

- GBD 2019 Collaborators. Global mortality from dementia: application of a new method and results from the global burden of disease study 2019. Alzheimers Dement (N Y) 2021;7:e12200.
- Liang CS, Li DJ, Yang FC, Tseng PT, Carvalho AF, Stubbs B, et al. Mortality rates in Alzheimer's disease and non-Alzheimer's dementias: a systematic review and meta-analysis. Lancet Healthy Longev 2021; 2:e479-e488.
- Ryan J, Fransquet P, Wrigglesworth J, Lacaze P. Phenotypic heterogeneity in dementia: a challenge for epidemiology and biomarker studies. Front Public Health 2018;6:181.
- Lee YF, Hsu TW, Liang CS, Yeh TC, Chen TY, Chen NC, et al. The efficacy and safety of tube feeding in advanced dementia patients: a systemic review and meta-analysis study. J Am Med Dir Assoc 2021;22: 357-363.
- Rajamaki B, Hartikainen S, Tolppanen AM. The effect of comorbidities on survival in persons with Alzheimer's disease: a matched cohort study. BMC Geriatr 2021;21:173.
- van de Vorst IE, Vaartjes I, Geerlings MI, Bots ML, Koek HL. Prognosis of patients with dementia: results from a prospective nationwide registry linkage study in the Netherlands. BMJ Open 2015;5:e008897.
- 7. Smith E, Ismail Z. Mortality risk models for persons with dementia: a

systematic review. J Alzheimers Dis 2021;80:103-111.

- Haaksma ML, Eriksdotter M, Rizzuto D, Leoutsakos JS, Olde Rikkert MGM, Melis RJF, et al. Survival time tool to guide care planning in people with dementia. Neurology 2020;94:e538-e548.
- Mitchell SL, Miller SC, Teno JM, Davis RB, Shaffer ML. The advanced dementia prognostic tool: a risk score to estimate survival in nursing home residents with advanced dementia. J Pain Symptom Manage 2010; 40:639-651.
- Cermakova P, Szummer K, Johnell K, Fastbom J, Winblad B, Eriksdotter M, et al. Management of acute myocardial infarction in patients with dementia: data from SveDem, the Swedish Dementia Registry. J Am Med Dir Assoc 2017;18:19-23.
- Aspberg S, Stenestrand U, Köster M, Kahan T. Large differences between patients with acute myocardial infarction included in two Swedish health registers. Scand J Public Health 2013;41:637-643.
- Sadarangani T, Perissinotto C, Boafo J, Zhong J, Yu G. Multimorbidity patterns in adult day health center clients with dementia: a latent class analysis. BMC Geriatr 2022;22:514.
- Schubert CC, Boustani M, Callahan CM, Perkins AJ, Carney CP, Fox C, et al, Comorbidity profile of dementia patients in primary care: are they sicker? J Am Geriatr Soc 2006;54:104-109.
- Cheng CM, Chang WH, Chiu YC, Chen MH, Liao WT, Yang CH, et al. Risk score for predicting mortality in people with dementia: a nationwide, population-based cohort study in Taiwan with 11 years of followup. J Clin Psychiatry 2019;80:18m12629.
- Deardorff WJ, Barnes DE, Jeon SY, Boscardin WJ, Langa KM, Covinsky KE, et al. Development and external validation of a mortality prediction model for community-dwelling older adults with dementia. JAMA Intern Med 2022;182:1161-1170.
- Alashwal H, Diallo TM, Tindle R, Moustafa AA. Latent class and transition analysis of Alzheimer's disease data. Front Comput Sci 2020; 2:551481.
- Holliday R, Kinney AR, Smith AA, Forster JE, Liu S, Monteith LL, et al. A latent class analysis to identify subgroups of VHA using homeless veterans at greater risk for suicide mortality. J Affect Disord 2022;315: 162-167.
- Kim M, Wall MM, Kiran RP, Li G. Latent class analysis stratifies mortality risk in patients developing acute kidney injury after high-risk intraabdominal general surgery: a historical cohort study. Can J Anaesth 2019;66:36-47.
- Seng JJB, Kwan YH, Lee VSY, Tan CS, Zainudin SB, Thumboo J, et al. Differential health care use, diabetes-related complications, and mortality among five unique classes of patients with type 2 diabetes in Singapore: a latent class analysis of 71,125 patients. Diabetes Care 2020; 43:1048-1056.
- Huang JS, Yang FC, Chien WC, Yeh TC, Chung CH, Tsai CK, et al. Risk of substance use disorder and its associations with comorbidities and psychotropic agents in patients with autism. JAMA Pediatr 2021;175: e205371.
- Liang CS, Bai YM, Hsu JW, Huang KL, Ko NY, Chu HT, et al. The risk of sexually transmitted infections following first-episode schizophrenia among adolescents and young adults: a cohort study of 220 545 subjects. Schizophr Bull 2020;46:795-803.
- 22. Chen MH, Hsu JW, Huang KL, Bai YM, Ko NY, Su TP, et al. Sexually transmitted infection among adolescents and young adults with attention-deficit/hyperactivity disorder: a nationwide longitudinal study. J Am Acad Child Adolesc Psychiatry 2018;57:48-53.
- Chen MH, Lan WH, Hsu JW, Huang KL, Su TP, Li CT, et al. Risk of developing type 2 diabetes in adolescents and young adults with autism spectrum disorder: a nationwide longitudinal study. Diabetes Care 2016;39:788-793.
- Zhang B, Wang HE, Bai YM, Tsai SJ, Su TP, Chen TJ, et al. Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study. Gut 2021;70:85-91.
- 25. Cheng CL, Chien HC, Lee CH, Lin SJ, Yang YH. Validity of in-hospital

mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int J Cardiol 2015;201:96-101.

- Chen TB, Yiao SY, Sun Y, Lee HJ, Yang SC, Chiu MJ, et al. Comorbidity and dementia: a nationwide survey in Taiwan. PLoS One 2017;12: e0175475.
- Bunn F, Burn AM, Goodman C, Rait G, Norton S, Robinson L, et al. Comorbidity and dementia: a scoping review of the literature. BMC Med 2014;12:192.
- Poblador-Plou B, Calderón-Larrañaga A, Marta-Moreno J, Hancco-Saavedra J, Sicras-Mainar A, Soljak M, et al. Comorbidity of dementia: a cross-sectional study of primary care older patients. BMC Psychiatry 2014;14:84.
- Golüke NMS, Geerlings MI, van de Vorst IE, Vaartjes IH, de Jonghe A, Bots ML, et al. Risk factors of mortality in older patients with dementia in psychiatric care. Int J Geriatr Psychiatry 2020;35:174-181.
- Emerging Risk Factors Collaboration. Association of cardiometabolic multimorbidity with mortality. JAMA 2015;314:52-60.
- Kuźma E, Lourida I, Moore SF, Levine DA, Ukoumunne OC, Llewellyn DJ. et al. Stroke and dementia risk: a systematic review and meta-analysis. Alzheimers Dement 2018;14:1416-1426.
- 32. Delgado J, Masoli J, Hase Y, Akinyemi R, Ballard C, Kalaria RN, et al. Trajectories of cognitive change following stroke: stepwise decline towards dementia in the elderly. Brain Commun 2022;4:fcac129.
- Sampson EL, Blanchard MR, Jones L, Tookman A, King M. Dementia in the acute hospital: prospective cohort study of prevalence and mortality. Br J Psychiatry 2009;195:61-66.
- Maciejewska K, Czarnecka K, Szymański P. A review of the mechanisms underlying selected comorbidities in Alzheimer's disease. Pharmacol Rep 2021;73:1565-1581.
- 35. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-M156.
- Palmer K, Vetrano DL, Padua L, Romano V, Rivoiro C, Scelfo B, et al. Frailty syndromes in persons with cerebrovascular disease: a systematic review and meta-analysis. Front Neurol 2019;10:1255.
- 37. Middleton R, Poveda JL, Orfila Pernas F, Martinez Laguna D, Diez Perez A, Nogués X, et al. Mortality, falls, and fracture risk are positively associated with frailty: a SIDIAP cohort study of 890 000 patients. J Gerontol A Biol Sci Med Sci 2022;77:148-154.
- Iwai-Saito K, Shobugawa Y, Aida J, Kondo K. Frailty is associated with susceptibility and severity of pneumonia in older adults (A JAGES multilevel cross-sectional study). Sci Rep 2021;11:7966.
- 39. Salminen M, Viljanen A, Eloranta S, Viikari P, Wuorela M, Vahlberg T,

et al. Frailty and mortality: an 18-year follow-up study among Finnish community-dwelling older people. Aging Clin Exp Res 2020;32:2013-2019.

- Koria LG, Sawan MJ, Redston MR, Gnjidic D. The prevalence of frailty among older adults living with dementia: a systematic review. J Am Med Dir Assoc 2022;23:1807-1814.
- Phelan EA, Borson S, Grothaus L, Balch S, Larson EB. Association of incident dementia with hospitalizations. JAMA 2012;307:165-172.
- 42. Müther J, Abholz HH, Wiese B, Fuchs A, Wollny A, Pentzek M. Are patients with dementia treated as well as patients without dementia for hypertension, diabetes, and hyperlipidaemia? Br J Gen Pract 2010; 60:671-674.
- 43. Keenan TD, Goldacre R, Goldacre MJ. Associations between age-related macular degeneration, Alzheimer disease, and dementia: record linkage study of hospital admissions. JAMA Ophthalmol 2014;132:63-68.
- 44. Browne J, Edwards DA, Rhodes KM, Brimicombe DJ, Payne RA. Association of comorbidity and health service usage among patients with dementia in the UK: a population-based study. BMJ Open 2017;7: e012546.
- Lee KC, Hsu WH, Chou PH, Yiin JJ, Muo CH, Lin YP. Estimating the survival of elderly patients diagnosed with dementia in Taiwan: a longitudinal study. PLoS One 2018;13:e0178997.
- 46. Connolly A, Gaehl E, Martin H, Morris J, Purandare N. Underdiagnosis of dementia in primary care: variations in the observed prevalence and comparisons to the expected prevalence. Aging Ment Health 2011;15:978-984.
- Tilburgs B, Vernooij-Dassen M, Koopmans R, van Gennip H, Engels Y, Perry M. Barriers and facilitators for GPs in dementia advance care planning: a systematic integrative review. PLoS One 2018;13:e0198535.
- Pimouguet C, Rizzuto D, Schön P, Shakersain B, Angleman S, Lagergren M, et al. Impact of living alone on institutionalization and mortality: a population-based longitudinal study. Eur J Public Health 2016; 26:182-187.
- 49. Kelaiditi E, Andrieu S, Cantet C, Vellas B, Cesari M; ICTUS/DSA Group. Frailty index and incident mortality, hospitalization, and institutionalization in Alzheimer's disease: data from the ICTUS study. J Gerontol A Biol Sci Med Sci 2016;71:543-548.
- Rizzuto D, Melis RJF, Angleman S, Qiu C, Marengoni A. Effect of chronic diseases and multimorbidity on survival and functioning in elderly adults. J Am Geriatr Soc 2017;65:1056-1060.
- Mayeda ER, Glymour MM, Quesenberry CP, Johnson JK, Pérez-Stable EJ, Whitmer RA. Survival after dementia diagnosis in five racial/ethnic groups. Alzheimers Dement 2017;13:761-769.



Supplementary Figure 1. Comorbiditity and characteristic clusters among patients with dementia from latent class analysis. Cluster 1: Low comorbidity class. Cluster 2: Cardiometabolic multimorbidity class. Cluster 3: FRINGED class (characterized by FRacture, Infection, Naso-Gastric feeding, and bleEDing over upper gastrointestinal tract).